HK stocks fluctuate | Akeso (09926) is up nearly 5%, and the biggest uncertainty of its Yiviva MAb has been resolved, it is expected to be listed overseas in the future.

Akeso (09926) is currently up nearly 5%, as of press time, up 4.83% at HKD 40.15, with a turnover of HKD 0.224 billion.

Zhitong Finance02:07 ET

[Brokerage Focus] Guolian Securities maintains its "buy" rating on Akeso Bio (09926) and suggests potential approval for two self-immune and lipid-lowering drugs outside the cancer field.

Guolian Securities published a research report, stating that Akeso (09926) is the first domestic enterprise to commercialize dual-antibody products. It has established a layout for tumor-targeting dual antibodies, immune evasion, and lipid-lowering drugs. Established in 2012, the company now has over a hundred varieties of drugs, including Cardunali and Pemigatinib, of which the cervical cancer drug Cardunali achieved annual sales of over 1 billion yuan; the lung cancer drug Ivosidenib is currently in development with an upfront payment of 0.5 billion yuan, and is expected to be released domestically and internationally by 2024; with two immune evasion and lipid-lowering drugs expected to be approved for non-tumor markets by 2024. The bank predicts that the company will reach

金吾財訊Jul 9 03:08 ET

HuaFu Securities: First time issuing a "buy" rating for Akeso (09926), target price of HK$55.85.

Huafu Securities predicts that Akeso's (09926) revenue will be 2.57 billion yuan, 3.98 billion yuan, and 6.15 billion yuan from 2024 to 2026, respectively.

Zhitong FinanceJul 8 22:06 ET

Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).

Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.

Zhitong FinanceJul 8 20:58 ET

Guosen Securities: Q2 performance under short-term pressure, 24H2 pharmaceutical industry is expected to reach bottom and rebound.

Since 2024, the pharmaceutical sector has been impacted by macroeconomic environment and policies both domestically and abroad, with both A-share and H-share pharmaceutical indices falling by more than 20%, and the number of stocks in the sector that have risen is no more than 10%.

Zhitong FinanceJul 8 03:29 ET

HK stocks surge | Akeso (09926) rose more than 4% in the afternoon, experts are bullish on the success rate of Eveloce overseas, with safety as a key advantage.

Akeso (09926) rose more than 4% in the afternoon. As of press time, it rose by 4.11%, at HKD 38, with a transaction amount of 0.154 billion Hong Kong dollars.

Zhitong FinanceJul 5 01:38 ET